Medicines Advisory Committee

Term

1 January 2024 - 31 December 2026

Scope

The Medicines Advisory Committee (MAC) provides advice to HPRG, including:

• Quality, safety and efficacy of medicines for marketing authorisation.
• Continued safety and effectiveness of medicines after marketing authorisation.
• Public interest consideration for marketing authorisation of medicines.
• Clinical consideration on the use of investigational drugs in clinical trials.
• Regulatory policies related to clinical use or supply of medicines.

Committee members

• Prof Fong Kok Yong (Chairman)
• Dr Khoo Kei Siong (Deputy Chairman)
• A/Prof Chan Cheng Leng (Secretary)
• Prof Philip Choo
• Prof Chua Hong Choon
• A/Prof Nagaendran Kandiah
• A/Prof Ravindran Kanesvaran
• Adj A/Prof Lim Yean Teng
• Dr Leong Hoe Nam
• Dr Shen Liang
• A/Prof Sum Chee Fang
• Prof Tan Chee Kiat
• Prof Tan Thuan Tong
• Dr Camilla Wong

Medical Devices Advisory Committee

Term

1 January 2024 - 31 December 2026

Scope

The Medical Devices Advisory Committee (MDAC) provides advice to HPRG, including:

• Quality, safety, efficacy and/or performance of medical devices for marketing authorisation.
• Continued safety and effectiveness of medical devices after marketing authorisation.
• Public interest consideration for marketing authorisation of medical devices.
• Regulatory policies related to clinical use or supply of medical devices.

Committee members

• Prof Tan Huay Cheem (Chairman)
• Prof Lawrence Ho Khek Yu (Deputy Chairman)
• A/Prof Chan Cheng Leng (Secretary)
• A/Prof Raymond Lin Tzer Pin
• A/Prof Joyce Koh Suang Bee
• Dr Martin H'ng Weng Chin
• A/Prof Kenny Sin Yoong Kong
• A/Prof Patrick Tseng Seng Kwong
• Adj A/Prof Adrian Koh Jit Hin
• A/Prof Ngiam Kee Yuan

Complementary Health Products Advisory Committee

Term

1 January 2024 - 31 December 2026

Scope

The Complementary Health Products Advisory Committee (CHPAC) provides advice to HPRG, including:

• Quality and safety of complementary health products for local supply.
• Continued quality and safety of complementary health products after local supply.
• Public interest and/or other considerations for local supply of complementary health products.
• Considerations on the use of investigational complementary health products in clinical trials.
• Regulatory policies related to the use and supply of complementary health products.

Committee members

• Prof Chin Jing Jih (Chairman)
• A/Prof Kong Keng He (Deputy Chairman)
• Ms Lee Hui Keng (Secretary)
• Ms Chan Soo Chung
• Dr Kim Jung Eun
• A/Prof Koh Hwee Ling
• Dr Joel Lee
• Dr Zhao Yan
• Dr Zheng Huang Fang
  
  

Product Vigilance Advisory Committee

Term

1 August 2023 - 31 July 2026

Scope

The Product Vigilance Advisory Committee (PVAC) provides scientific advice to HPRG in relation to the continued availability and safe use of health products in Singapore, through the following:

• To review the benefit-risk profile of health products, assess the impact of significant safety issues associated with health products and advise on the appropriate regulatory actions to be taken to minimise the risk associated with the use of these products.
• To review serious selected adverse event reports, and advise on the causality assessment and appropriate follow-up actions to be initiated by HSA.
• To provide guidance on innovative post-marketing surveillance tools.
• To be an advocate of health products vigilance and actively promote adverse event reporting by healthcare professionals.
• To contribute to HSA’s educational programmes on health product safety in Singapore.

Committee members

• Prof Goh Chee Leok (Chairman)
• A/Prof Sum Chee Fang (Deputy Chairman)
• Ms Jalene Poh (Secretary)
• A/Prof Jason Choo
• A/Prof Chow Wan Cheng
• A/Prof Ding Zee Pin
• Prof Derrick Heng
• Dr Belinda Lee
• Emeritus Prof Edmund Lee
• Dr Shen Liang
• Dr Tan Lip Kun
• Clinical Prof Tan Thuan Tong
• Adj A/Prof Tan Tze Lee
• Adj A/Prof Bernard Thong
• Dr Camilla Wong

Clinical Trials Advisory Committee

Term

1 August 2023 - 31 July 2026

Scope

The Clinical Trials Advisory Committee (CTAC) provides advice to HPRG, including:

• First in human (FIH) clinical trials of new investigational products with a novel target or a mechanism of action that is novel or currently not well characterised.
• FIH clinical trials of novel investigational products where animal data are unlikely to be predictive of activity in humans.
• Clinical trials where there is an equivocal benefit risk assessment.
• Clinical trials where specific safety issues have been identified.
• Clinical trials where there are study design-related concerns.
• Clinical trials where there are manufacturing-related concerns impacting on the safety of the investigational products.
• Innovation Office consultations requiring expert advice.

Committee members

• Prof Edmund Lee (Chair)
• Prof Laurent Renia (Deputy Chair)
• Dr Lisa Tan (Secretary)
• Prof Ashok Venkitaraman
• Prof Vasudevan Subhash
• A/Prof Ho Han Kiat
• Dr Francesca Lim

Panel of Advisors for the HSA Proficiency Testing (PT) Programme in Chemical Testing

Term

1 April 2023 - 31 March 2025

Scope

The Panel of Advisors for the HSA Proficiency Testing (PT) Programme in Chemical Testing provides advice to ASG, including:

• Issues that the Panel considers to be of major strategic significance to the PT programme.
• Choice of the test materials, analytes and their concentration ranges.
• Frequency of the programme.
• Design and implementation of the programme.
• Methods of evaluation of results.
• Comment on contents of reports.
• Interpretation of the performance of participating laboratories.

Committee members

• Adj A/Prof Chan Sheot Harn (Chairperson)
• Dr Zhang Lifeng
• Dr Yong Kuang Chih
• Dr Hou Xinping
• Ms Low Min Yong

Panel of Advisors for the HSA External Quality Assessment (EQA) Programme in Clinical Chemistry

Term

1 April 2022 - 31 March 2025

Scope

The Panel of Advisors for the HSA External Quality Assessment (EQA) Programme in Clinical Chemistry provides advice to ASG, including:

• Issues that the Panel considers to be of major strategic significance to the EQA programme.
• Choice of the test materials, analytes and their concentration ranges.
• Frequency of the programme.
• Design and implementation of the programme.
• Methods of evaluation of results.
• Comment on contents of reports.
• Interpretation of the performance of participating laboratories.

Committee members

• A/Prof Wong Moh Sim (Chairperson)
• A/Prof Sunil Sethi
• A/Prof Yeo Chin Pin
• Dr Lam Choong Weng Leslie
• Dr Loh Tze Ping